Updated time: 2021-03-12 11:41:38
28A-1030410
US 10793628 B2、TW pending
Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed.
Current treatment procedures available for pancreatic cancer have not led to a cure, nor to a substantially improved survival time. Surgical resection has been the only modality that offers a chance at survival. However, due to a large tumor burden, only 10% to 25% of patients are candidates for "curative resection." For those patients undergoing a surgical treatment, the five-year survival rate is still poor, averaging only about 10%.
Treatment for breast cancer and pancreatic cancer
LEE, WEN-HWA、SHEW, JIN-YUH、MA, CHE、CHEN, CHIA-LIN、LEE, WEN-HSIN、HUANG, CHUN-KAI、WU, HENG-HSIUNG
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

ANTAGONISTS FOR INTERLEUKIN-17 RECEPTOR B (IL-17RB) AND ITS LIGAND IL-17B FOR CANCER THERAPY